Panaxadiol
Catalog No: CFN99981
Panaxadiol, an anti-hepatitis B virus inhibitor, exhibits anticancer, cardioprotective, anti-arrhythmic, and antioxidative activities. It inhibits Ca2+ channels, decreasing channel open time and open state probability in vitro and displaying anti-arrhythmic potential. Panaxadiol selectively interferes with the cell cycle in human cancer cell lines, it inhibits DNA synthesis in a dose-dependent manner with IC50 values ranging from 0.8 to 1.2 μM in SK-HEP-1 cells and HeLa cells, it selectively elevates p21WAF1/CIP1 levels and thereby arrests the cell cycle at G1/S phase by down-regulating Cyclin A–Cdk2 activity.
Panaxatriol
Catalog No: CFN99982
Panaxatriol is an inducer of thioredoxin-1 (Trx-1), which exhibits anti-inflammatory, hepatoprotective, anti-arrhythmic, and antioxidative activities. It has pluripharmacological properties in the protection against Parkinson's disease (PD) including enhancing antioxidant activity, acting as neurotrophic factor, modulating inflammation and inhibiting mitochondria-mediated apoptosis. Panaxatriol has been shown to be efficacious in the prevention and treatment of cerebrovascular diseases in China, it may activate endogenous cytoprotective mechanism against OGD-Rep induced oxidative injury via the activation of PI3K/Akt and Nrf2 signaling pathway.
Panaxydol
Catalog No: CFN92797
Panaxydol has anti-cancer activity, can inhibit the growth and apoptosis of cancer cells, the signaling mechanisms involve a [Ca(2+)](i) increase, JNK and p38 MAPK activation, cAMP, MAP kinase and ROS generation through NADPH oxidase and mitochondria. It induces the differentiation in C6 cells, may through a PI 3-K-dependent pathway.
